At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 260 enrolled
Drug / intervention
JTE-051 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis (MOVE-RA)
In Brief
A Phase 2 clinical trial evaluating JTE-051 and Placebo for Rheumatoid Arthritis. Completed, enrolled 260 participants across 39 sites in 10 countries.
Detailed Summary
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of JTE-051 administered for 12 weeks in subjects with active rheumatoid arthritis who are receiving background non-biologic disease-modifying anti-rheumatic drug therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesArgentina, Bulgaria, Colombia, Mexico, Peru, Poland, Romania, Russia, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartSep 2016
First PostedSep 2016
Primary CompletionJun 2018
TodayJul 2026
First PostedSep 29, 2016
Enrollment StartSep 14, 2016
Primary CompletionJun 25, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.8 years ago
Interventions
JTE-051drug
Active drug tablets containing JTE-051
Placebodrug
Placebo tablets identical in appearance to the active drug tablets